Back to Journals » International Journal of Nanomedicine » Volume 7

Targeting nanomaterials: future drugs for cancer chemotherapy

Authors Zhang, Chen T

Received 13 August 2012

Accepted for publication 17 August 2012

Published 10 October 2012 Volume 2012:7 Pages 5283—5286


Yibo Zhang, Tianfeng Chen

Department of Chemistry, Jinan University, Guangzhou, China

Concerning the recent articles published in your journal on multifunctional nanosystem for cancer chemotherapy.1 It should be an admirable approach to kill cancer cells, with the least side effects on normal tissues and cells. During the past few decades, various chemotherapeutic agents, such as cyclophosphamide, fluorouracil, platinum-based compounds, anthracycline, hydroxycamptothecin and paclitaxel, have been designed and proved to be effective toward cancer cells. However, regrettably, these drugs are non-targeted to cancer, and thus serious side effects to normal cells or tissues are unavoidable.2 Therefore, new drugs with selective cytotoxicity become an important research focus in cancer chemotherapy. Another obstacle for chemotherapy is the multidrug resistance. Actually, several targeted drugs such as RTK inhibitors, FTase inhibitors, tumor angiogenesis inhibitors, campath, avastin and erbitux, have been commercialized and widely used clinically.3 However, drug resistance seriously limited their anticancer efficacy. Nanotechnology-based approaches are anticipated to provide a new breakthrough for targeting cancer cells and bypassing their multidrug resistance.4

View original paper by Wang and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]